New Data Further Links Lipoprotein Particles to Cardiovascular Disease Risk

New Data Further Links Lipoprotein Particles to Cardiovascular Disease Risk

Findings Presented at the ACC Annual Scientific Sessions

RALEIGH, N.C.--(BUSINESS WIRE)-- LipoScience, Inc. (Nasdaq: LPDX  ) an in vitro diagnostic company committed to advancing patient care in cardiovascular, metabolic and other diseases, today announced the presentation of data from two studies, at the Annual Scientific Session of the American College of Cardiology (ACC) in San Francisco, highlighting the importance of low density lipoprotein particle (LDL-P) measurements in identifying cardiovascular disease risk for patients.

Previous studies have indicated that many patients with relatively normal levels of low density lipoprotein cholesterol (LDL-C) have increased LDL-P, illustrating discordance between the two measures of LDL. The medical community is increasingly aware of the critical role utilizing LDL-P as measured by nuclear magnetic resonance (NMR) spectroscopy to help manage a patient’s cardiovascular disease risk. The data presented at ACC further validates the need for increased awareness of LDL-P as an indicator of cardiovascular disease, and the value of NMR as a differentiated platform technology.

Discordance in Low-Density Lipoprotein Particle Number (LDL-P) and Apolipoprotein B (Apo B) Level

On Saturday, March 9, Dr. Pamela Morris, M.D., FACC of the Medical University of South Carolina, presented data from the study “Discordance in Low-Density Lipoprotein Particle Number (LDL-P) and Apolipoprotein B (Apo B) Level” highlighting the relationship between these two biomarkers in assessing cardiovascular risk. The study examined the Apo B and LDL-P values of 1,196 subjects. Ultimately, it was found that a considerable percentage of patients had much higher LDL-P levels despite attaining normal levels of Apo B.

“In some cases, LDL cholesterol and LDL particle numbers do not agree, leaving seemingly healthy patients with hidden risk for cardiovascular events,” said Dr. Morris, an author of this study. “The data presented shows that the same is true for Apo B and LDL-P. Discordance is a potential concern amongst these biomarkers, illuminating the need for a complete picture of heart health. Physicians should not rely solely on one diagnostic measure—it is necessary to examine both LDL-C and LDL-P to manage patient care.”

NMR-Based Lipoprotein Particle Profiling Identifies Novel Signatures for Cardiovascular Disease

Another presentation, “NMR-Based Lipoprotein Particle Profiling Identifies Novel Signatures for Cardiovascular Disease,” explored the associations of LDL-P with cross sectional coronary artery disease (CAD) and CAD severity, and the potential as a predictor of incident cardiovascular events. The study analyzed plasma from 1,736 patients who were enrolled in the CATHGEN biorepository of patients undergoing cardiac catheterization at Duke University Medical Center. The study found novel lipoprotein signatures that independently discriminate the presence and extent of CAD and predict incident mortality and myocardial infarction.

“This study contributes to the growing body of research linking lipoprotein particle number to increased risk for cardiovascular disease,” said William E. Kraus, M.D., Professor of Cardiology at Duke University, and an author of the study. “By analyzing LDL-P by NMR spectroscopy, we were able to determine that lipoprotein size and concentration are novel biomarkers for CAD discrimination and mortality prediction.”

LDL-P was measured in both studies using LipoScience’s NMR LipoProfile® test, a laboratory test that utilizes NMR spectroscopy to measure LDL particle number and standard lipid values. LDL-P information can help clinicians personalize and refine LDL management decisions, particularly to minimize residual risk in patients with low LDL cholesterol levels.

LipoScience ACC Poster Presentations Details:

  • Discordance in Low-Density Lipoprotein Particle Number (LDL-P) and Apolipoprotein B (Apo B) Level
    Date: Saturday, March 9, 2013
    Time: 3:45 p.m.-4:30 p.m.
    Location: Poster Sessions, Expo North
  • NMR-Based Lipoprotein Particle Profiling Identifies Novel Signatures for Cardiovascular Disease
    Date: Monday, March 11, 2013
    Time: 9:45 a.m.-10:30 a.m.
    Location: Poster Sessions, Expo North

For more information on LipoScience, please visit www.liposcience.com or the LipoScience, Inc. booth at #S943.

About LipoScience, Inc.

LipoScience, Inc. is pioneering a new field of personalized diagnostics based on nuclear magnetic resonance (NMR) technology. Its first proprietary diagnostic test, the NMR LipoProfile® test, measures the number of low density lipoprotein particles (LDL-P) in a blood sample and provides physicians and their patients with actionable information to personalize management of risk for heart disease. To date, over 9 million NMR LipoProfile tests have been ordered. LipoScience’s automated clinical analyzer Vantera®, has been cleared by the FDA. It requires no previous knowledge of NMR technology to operate and has been designed to dramatically simplify complex technology through ease of use and walk away automation. The Vantera system will be placed with national and regional clinical laboratories.

LipoScience is driving toward becoming a clinical standard of care by decentralizing its technology and expanding its menu of personalized diagnostic tests to address a broad range of cardiovascular, metabolic and other diseases. For further information on LipoScience, please visit www.liposcience.com and www.theparticletest.com.



Schwartz MSL
Stacey Holifield/Taylor Ramsey, 781-684-0770
liposcience@schwartzmsl.com
or
LipoScience, Inc.
Tori Hall, 919-256-1046
tori.hall@liposcience.com

KEYWORDS:   United States  North America  California  North Carolina

INDUSTRY KEYWORDS:

Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.


Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2305402, ~/Articles/ArticleHandler.aspx, 11/23/2014 2:35:37 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...